Ajanta Pharma
Ajanta Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
India business is expected to grow at mid-teens (around 16-18%) in FY27. Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%.
From Ajanta Pharma's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business is expected to grow at mid-teens (around 16-18%) in FY27.
- Asia business is guided for high double-digit growth next year, recovering from logistics delays.
- Africa business targeted for high double-digit growth.
- US generics business to grow at mid-single digit in the coming year after strong 49% growth in FY26.
- Chronic therapy areas (around 50% of combined Asia and Africa branded generics market) will remain a focus.
- Gynaecology segment in India showing encouraging progress, expected to contribute meaningfully over next 2-3 years.
- Nephrology segment in India developing slowly, positive signs but longer gestation.
- Overall company targeting revenue growth in the high teens (~16-18%) for FY27.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure for FY 2026 stood at Rs. 330 crores, in line with guidance.
- Ajanta Pharma is embarking upon a new capex cycle to meet continued growth requirements.
- For FY 2027, capex is expected to increase to around Rs. 400 crores.
- Of this, Rs. 150 crores is allocated for maintenance, and the balance for new capacity expansion.
- The company is investing in product range expansion and addition of medical representatives across geographies.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Ajanta Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.4K Cr, net profit ₹267 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Ajanta Pharma Q4 FY26 results?
India business is expected to grow at mid-teens (around 16-18%) in FY27. Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%.
What is Ajanta Pharma share price analysis?
Ajanta Pharma currently shows a below-average growth signal. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma planning capital expenditure?
Capital expenditure for FY 2026 stood at Rs.
Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.